Navigation Links
Business of drug development on verge of great change

Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping transform the business of drug research and development.

According to Christopher Austin, M.D., director of the NIH Chemical Genomics Center (NCGC), both industry and academia welcome more cooperation in drug discovery to secure more efficient results for less financial burden than if they operate independently. The increased participation of the public sector in therapeutics development is a trend that will be good for industry, academia, scientific discovery and the public at large, says Dr. Austin.

These collaborative efforts have been facilitated by researchers moving from industry to academia to help close the gap that exists between basic early stage research and the identification of viable drug candidates for a range of diseases, particularly those that are less prevalent or for which the targets are less well validated. The hope is that better drugs to treat more diseases will be developed faster and less expensively than ever before.

Not only is Dr. Austin a scientist who wants his work to improve the lives of people affected by disease, he also is a former pharmaceutical industry researcher who understands the business of drug development, having previously worked at Merck & Co. for a number of years. Hes observed that industry scientists are constrained in the scope of targets and diseases they study by commercial regulations imperatives which do not exist in the public sector. The work we do at the NCGC is complementary to what industry does we work on the 90% of new targets and diseases that industry doesnt, and we make our data publicly available so all researchers, public and private, can use it to advance drug discovery.

Marcie Glicksman, Ph.D., senior director of lead discovery, laboratory of drug discovery at the Harvard NeuroDiscovery Center and one of several co-presenters at the SBS meeting, also came from industry and has high hopes for the increased collaboration between Big Pharma and academia in drug discovery. At Harvard, our mission is to develop new therapeutics for diseases with no disease modifying treatments such as Parkinsons and Alzheimers, or orphan diseases such as Huntingtons and Amyotrophic Lateral Sclerosis (Lou Gehrigs), she states. There are smaller numbers of patients affected by orphan diseases -- treatments for them are not considered billion dollar drugs, so they are much harder to develop in industry.

Like Dr. Austin, Dr. Glicksman says its simply too expensive for industry to conduct this early stage research, and that is why the academic centers are so vital to the future of drug discovery for diseases that industry cant address on its own.

Dr. Austin and Dr. Glicksman will speak at a session on this topic at the 14th Annual Conference & Exhibition of the Society for Biomolecular Sciences (SBS) April 6-10 at Americas Center in St. Louis.


Contact: Jennifer Bender
203-325-8772 x18
Society for Biomolecular Sciences

Related medicine news :

1. Underwriters Laboratories Management System Registration Business to Merge With Germanys DQS
2. Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum
3. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
6. Barr Announces Reorganization of Senior Management, Business Functions
7. Small Business Health Care Survey Points to Need for Reform
8. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
9. Adds Vice President of Business Development
10. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
11. Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc.
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... ... On November 10, 2015, Bohrer Brady, LLC filed a class and collective ... home health care worker who provided companionship services for the elderly, ill or disabled ... Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since January ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: AGN ... the New York State Attorney General,s ... Sherman Act, and other statutes with the Attorney General over ... to cease marketing and selling the now generic version of ... admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: